The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.
View full OBJ profile
October 26 2016
February 11 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”